Comparison of oral Betahistine and intramuscular promethazine in treatment of acute peripheral vertigo in emergency department

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015062022834N1

Enrollment

160

Registered

2015-07-11

Start date

2015-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute peripheral vertigo. Diseases of the ear and mastoid process

Interventions

Intervention 1: Betahistine 8 mg as treatment and stilled water 2 ml as placebo was given to first group. Intervention 2: Promethazine 25 mg intramuscle and oral placebo was given to second group.

Treatment - Drugs

Betahistine 8 mg as treatment and stilled water 2 ml as placebo was given to first group

Promethazine 25 mg intramuscle and oral placebo was given to second group

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients aged 18-65 years old with peripheral acute vertigo. Exclusion criteria: contraindications of promethazin and betahistine; pregnant and breast feeding women; central vertigo.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Symptom control. Timepoint: 0, 1, 2 and 4 hours after treatment. Method of measurement: VAG score.	—

Secondary

Measure	Time frame
Occurance of drug side effects. Timepoint: During the first 4 hours. Method of measurement: Monitoring the patient.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMeisam Moezi

Jundishapur University of Medical Sciences

Meisam-88@yahoo.com; moezi_m@ajums.ac.ir+98 61 3374 3001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026